ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Stronghold Plus 15 mg/2.5 mg spot-on solution for cats ≤2.5 kg
Stronghold Plus 30 mg/5 mg spot-on solution for cats >2.5–5 kg
Stronghold Plus 60 mg/10 mg spot-on solution for cats >5–10 kg

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each unit dose (pipette) delivers:

Active substances:

<table>
<thead>
<tr>
<th>Stronghold Plus spot-on solution</th>
<th>Pipette content (ml)</th>
<th>selamectin (mg)</th>
<th>sarolaner (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cats ≤2.5 kg</td>
<td>0.25</td>
<td>15</td>
<td>2.5</td>
</tr>
<tr>
<td>Cats &gt;2.5–5 kg</td>
<td>0.5</td>
<td>30</td>
<td>5</td>
</tr>
<tr>
<td>Cats &gt;5–10 kg</td>
<td>1</td>
<td>60</td>
<td>10</td>
</tr>
</tbody>
</table>

Excipients:
0.2 mg/ml butylated hydroxytoluene.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Spot-on solution.
Clear, colourless to yellow solution.

4. CLINICAL PARTICULARS

4.1 Target species

Cats.

4.2 Indications for use, specifying the target species

For cats with, or at risk from, mixed parasitic infestations by ticks and fleas, lice, mites, gastrointestinal nematodes or heartworm. The veterinary medicinal product is exclusively indicated when use against ticks and one or more of the other target parasites is indicated at the same time.

Ectoparasites:

- For the treatment and prevention of flea infestations (Ctenocephalides spp.). The veterinary medicinal product has immediate and persistent flea killing activity against new infestations for 5 weeks. The product kills adult fleas before they lay eggs for 5 weeks. Through its ovicidal and larvicidal action, the veterinary medicinal product may aid in the control of existing environmental flea infestations in areas to which the animal has access.

- The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

- Treatment of tick infestations. The veterinary medicinal product has immediate and persistent acaricidal effect for 5 weeks against Ixodes ricinus and Ixodes hexagonus, and 4 weeks against Dermacentor reticulatus and Rhipicephalus sanguineus.
- Treatment of ear mites (*Otodectes cynotis*).
- Treatment of biting lice infestations (*Felicola subrostratus*).

Ticks must attach to the host and commence feeding in order to be exposed to sarolaner.

**Nematodes:**
- Treatment of adult roundworms (*Toxocara cati*) and adult intestinal hookworms (*Ancylostoma tubaeforme*).
- Prevention of heartworm disease caused by *Dirofilaria immitis* with monthly administration.

### 4.3 Contraindications

Do not use in cats that are suffering from concomitant disease, or are debilitated and underweight (for size and age).

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

### 4.4 Special warnings for each target species

It is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more, living in countries where a vector exists should be tested for existing adult heartworm infections before beginning preventive use with the veterinary medicinal product.

This veterinary medicinal product is not effective against adult *D. immitis*. The administration to animals with adult heartworm infection did not pose safety concerns.

Whilst not routinely indicated, the potential benefits of performing periodic testing for heartworm infection in individual cases should be considered by the responsible veterinarian.

Ticks need to start feeding on the host to become exposed to sarolaner; therefore, the transmission of infectious tick-borne diseases cannot be excluded.

### 4.5 Special precautions for use

**Special precautions for use in animals**

Use of this veterinary medicinal product is indicated in cats aged at least 8 weeks old and weighing at least 1.25 kg bodyweight.

This veterinary medicinal product is to be applied to the skin surface only. Do not administer orally or parenterally.

Do not apply when the animal’s hair coat is wet.

For ear mite treatment, do not apply directly to the ear canal. It is important to apply the dose as indicated to prevent the animal from licking and ingesting the product. If significant ingestion occurs, transient gastrointestinal effects such as hypersalivation, emesis, soft faeces or reduced food consumption may be observed and should normally resolve without treatment.

Keep treated animals away from fires and other sources of ignition for at least 30 minutes or until the hair coat is dry.
Special precautions to be taken by the person administering the veterinary medicinal product to animals

The product is harmful after ingestion. Keep the product in the original packaging until use, in order to prevent children from getting direct access to the product. Used pipettes should be disposed of immediately. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

The product may cause eye irritation. Avoid eye contact including hand-to-eye-contact. Avoid direct contact with treated animals until the application area is dry. Wash hands after use and wash off any product in contact with the skin immediately with soap and water. If accidental eye exposure occurs, flush the eyes immediately with water and seek medical attention.

Children are not allowed to play with treated cats for 4 hours after treatment. It is recommended to treat animals in the evening. On the day of treatment, treated animals should not be permitted to sleep in the same bed as their owner, especially children.

People with sensitive skin or known allergy to veterinary medicinal products of this type should handle the veterinary medicinal product with caution.

The product is highly flammable. Keep away from heat, sparks, open flame or other sources of ignition.

4.6 Adverse reactions (frequency and seriousness)

Use of the veterinary medicinal product may result in mild and transient pruritus at the application site. Mild to moderate alopecia at the application site, erythema and drooling have been uncommonly observed.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).

4.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation or in animals intended for breeding. However, selamectin is considered safe for use in breeding, pregnant and lactating cats. While the safety of sarolaner has not been evaluated in breeding, pregnant or lactating cats, laboratory studies with sarolaner in rats and rabbits have not produced any evidence of teratogenic effects. Use only according to the benefit-risk assessment by the prescribing veterinarian.

4.8 Interaction with other medicinal products and other forms of interaction

During clinical field testing, no interactions between this veterinary medicinal product and routinely used veterinary medicinal products were observed.

4.9 Amounts to be administered and administration route

Spot-on use.

Stronghold Plus should be administered as a single spot-on (topical) application in accordance with the following table (corresponding to a minimum of 6 mg/kg selamectin and 1 mg/kg sarolaner).
<table>
<thead>
<tr>
<th>Bodyweight of cat (kg)</th>
<th>Pipette content (ml)</th>
<th>Strength and number of pipettes to be administered</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Stronghold Plus 15 mg/2.5 mg (yellow cap)</td>
</tr>
<tr>
<td>≤2.5</td>
<td>0.25</td>
<td>1</td>
</tr>
<tr>
<td>&gt;2.5–5</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>&gt;5–10</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>&gt;10</td>
<td></td>
<td>Appropriate combination of pipettes</td>
</tr>
</tbody>
</table>

Method and route of administration

Apply topically to the skin at the base of the neck in front of the shoulder blades. The pipette should be removed from the protective package immediately prior to administration.

Holding the pipette upright, firmly depress the cap to puncture the applicator seal, then remove the cap.

Part the hair at the base of the cat’s neck in front of the shoulder blades to expose a small area of skin. Apply the tip of the pipette directly to the skin, without massaging.

Squeeze the pipette firmly 3–4 times to empty the contents in one spot. Avoid contact between the product and your fingers.

Transient cosmetic effects may occur at the application site such as temporary clumping or spiking of the hair, greasiness or dry white deposits, which normally resolve within 24 hours after product application. These effects do not affect the safety or efficacy of the veterinary medicinal product.

Treatment schedule

Fleas and ticks
For optimal control of tick and flea infestations, the veterinary medicinal product should be administered at monthly intervals and continued throughout the flea and/or tick season based on local epidemiological situations.

Following administration of the product, the adult fleas on the animal are killed within 24 hours, no viable eggs are produced, and larvae (found only in the environment) are also killed. This stops flea reproduction, breaks the flea lifecycle and may aid in the control of existing environmental flea infestations in areas to which the animal has access.

Prevention of heartworm disease
The product may be administered year-round or at least within one month of the animal’s first exposure to mosquitoes and monthly thereafter until the end of the mosquito season. The final dose
must be given within one month after the last exposure to mosquitoes. If a dose is missed and a monthly interval between dosing is exceeded, then immediate administration of the product and resumption of monthly dosing will minimise the opportunity for the development of adult heartworms. When replacing another heartworm preventive product in a heartworm disease prevention programme, the first dose of the product must be given within a month of the last dose of the former veterinary medicinal product.

Treatment of roundworm and hookworm infections
A single dose of the product should be administered. The need for and frequency of re-treatment should be in accordance with the advice of the prescribing veterinarian.

Treatment of biting lice
A single dose of the product should be administered.

Treatment of ear mites
A single dose of the product should be administered. Seek further veterinary examination 30 days after treatment to determine whether a second administration is necessary.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
No clinically significant adverse reactions were observed in kittens from 8 weeks of age treated with up to 5 times the maximum recommended dose of the product for up to 8 consecutive treatments at 28 day intervals, apart from a single cat administered 5 times the maximum dose that displayed transient hypersensitivity to touch, piloerection, mydriasis and mild tremor which resolved without treatment.

After accidental ingestion of a full product dose, transient gastrointestinal effects such as salivation, soft faeces, emesis, and reduced food consumption may occur, however these should resolve without treatment.

4.11 Withdrawal period(s)
Not applicable.

5. PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: Antiparasitic products, insecticides and repellents, macrocyclic lactones, combinations.
ATC vet code: QP54AA55.

5.1 Pharmacodynamic properties
Selamectin is a semi-synthetic compound of the avermectin class. Selamectin paralyzes and/or kills a wide range of invertebrate parasites through interference with their chloride channel conductance causing disruption of normal neurotransmission. This inhibits the electrical activity of nerve cells in nematodes and muscle cells in arthropods leading to their paralysis and/or death.

Selamectin has adulticidal, ovicidal and larvicidal activity against fleas. Therefore, it effectively breaks the flea life cycle by killing adults (on the animal), preventing the hatching of eggs (on the animal and in its environment) and by killing larvae (environment only). Debris from selamectin-treated pets kills flea eggs and larvae not previously exposed to selamectin and thus may aid in the control of existing environmental flea infestations in areas to which the animal has access. Selamectin is active against adult fleas (Ctenocephalides spp.) as well as mites (Otodectes cynotis), lice (Felicola subrostratus) and gastrointestinal nematodes (Toxocara cati, Ancylostoma tubaeforme). Activity has also been demonstrated against heartworm (D. immitis) larvae.
For fleas, the onset of efficacy is within 24 hours for 5 weeks after product application.

Sarolaner is an acaricide and insecticide belonging to the isoxazoline family. The primary target of action of sarolaner in insects and acarines is functional blockade of ligand-gated chloride channels (GABA-receptors and glutamate-receptors). Sarolaner blocks GABA- and glutamate-gated chloride channels in the central nervous system of insects and acarines. Disruption of these receptors by sarolaner prevents the uptake of chloride ions by GABA and glutamate gated ion channels, thus resulting in increased nerve stimulation and death of the target parasite. Sarolaner exhibits higher functional potency to block insect/acarine receptors compared to mammalian receptors. Sarolaner does not interact with known insecticidal binding sites of nicotinic or other GABAergic insecticides such as neonicotinoids, fiproles, milbemycins, avermectins, and cyclodienes. Sarolaner is active against adult fleas (*Ctenocephalides* spp.) as well as several tick species such as *Dermacentor reticulatus*, *Ixodes hexagonus*, *Ixodes ricinus*, and *Rhipicephalus sanguineus*.

For ticks (*I. ricinus*), the onset of efficacy is within 24 hours of attachment for one month after product application.

5.2 Pharmacokinetic particulars

Following topical administration of the Stronghold Plus both selamectin and sarolaner are well absorbed with bioavailability mean values of 40.5% and 57.9%, respectively and distribute systemically. In cats, selamectin and sarolaner are low clearance compounds with long half-life values, 12.5 days and 41.5 days respectively, following topical administration.

In cats the primary route of selamectin elimination is in faeces and the majority is parent compound. Identification of selamectin metabolites in faeces indicated that metabolic clearance also contributes to the elimination. The primary route of elimination for sarolaner is biliary elimination of parent sarolaner, with contributions by metabolic clearance.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Butylated hydroxytoluene
Dipropylene glycol monomethyl ether
Isopropyl alcohol

6.2 Incompatibilities

None known.

6.3 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 30 months.

6.4 Special precautions for storage

Store below 30 °C.
Do not remove the pipette from the blister until ready to use.

6.5 Nature and composition of immediate packaging

Translucent polypropylene unit dose pipettes individually packed in aluminium and aluminium/PVC blisters.

The pipette caps are colour-coded as follows:
Pipettes with yellow caps contain 0.25 ml of product and deliver 15 mg selamectin and 2.5 mg sarolaner
Pipettes with orange caps contain 0.5 ml of product and deliver 30 mg selamectin and 5 mg sarolaner
Pipettes with green caps contain 1 ml of product and deliver 60 mg selamectin and 10 mg sarolaner

The product is available in packs of three pipettes (all pipette sizes) and six pipettes (all pipette sizes) placed in cardboard boxes. Not all pack sizes may be marketed.

6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Stronghold Plus should not enter water courses as this may be dangerous to aquatic organisms. Containers and residual contents should be disposed of along with collected domestic refuse to avoid contamination of any water courses.

7. MARKETING AUTHORISATION HOLDER

Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIUM

8. MARKETING AUTHORISATION NUMBER(S)

EU/2/16/204/001–006

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: {DD/MM/YYYY}

10 DATE OF REVISION OF THE TEXT

{MM/YYYY}

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.emea.europa.eu/).

PROHIBITION OF SALE, SUPPLY AND/OR USE

Not applicable.
ANNEX II

A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. STATEMENT OF THE MRLs
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer responsible for batch release

Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIUM

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Veterinary medicinal product subject to prescription.

C. STATEMENT OF THE MRLs

Not applicable.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Cardboard box

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Stronghold Plus 15 mg/2.5 mg spot-on solution for cats ≤2.5 kg
Stronghold Plus 30 mg/5 mg spot-on solution for cats >2.5–5 kg
Stronghold Plus 60 mg/10 mg spot-on solution for cats >5–10 kg

Selamectin/sarolaner

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

15 mg selamectin/2.5 mg sarolaner
30 mg selamectin/5 mg sarolaner
60 mg selamectin/10 mg sarolaner

3. PHARMACEUTICAL FORM

Spot-on solution

4. PACKAGE SIZE

3 pipettes
6 pipettes
0.25 ml
0.5 ml
1 ml

5. TARGET SPECIES

Cats

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Spot-on use.
Read the package leaflet before use.
8. WITHDRAWAL PERIOD

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP {month/year}

11. SPECIAL STORAGE CONDITIONS

Store below 30 °C.
Do not remove the pipette from the blister until ready to use.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIUM
16. MARKETING AUTHORISATION NUMBER(S)

EU/2/16/204/001 (3 x 0.25 ml)
EU/2/16/204/002 (6 x 0.25 ml)
EU/2/16/204/003 (3 x 0.5 ml)
EU/2/16/204/004 (6 x 0.5 ml)
EU/2/16/204/005 (3 x 1 ml)
EU/2/16/204/006 (6 x 1 ml)

17. MANUFACTURER’S BATCH NUMBER

Lot {number}
MINIMUM PARTICULARS TO APPEAR ON BLISTERS

BLISTER

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Stronghold Plus spot-on solution for cats

≤2.5 kg  >2.5–5 kg  >5–10 kg

Selamectin/sarolaner

2. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis Belgium SA

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

0.25 ml
0.5 ml
1 ml

4. BATCH NUMBER

Lot {number}

5. EXPIRY DATE

EXP {month/year}

6. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

PIPETTE

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Stronghold Plus ≤2.5 kg
Stronghold Plus >2.5–5 kg
Stronghold Plus >5–10 kg

2. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

0.25 ml
0.5 ml
1 ml

3. ROUTE(S) OF ADMINISTRATION

4. WITHDRAWAL PERIOD

5. BATCH NUMBER

Lot {number}

6. EXPIRY DATE

EXP {month/year}
B. PACKAGE LEAFLET
1. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder and manufacturer responsible for batch release:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIUM

2. **NAME OF THE VETERINARY MEDICINAL PRODUCT**

Stronghold Plus 15 mg/2.5 mg spot-on solution for cats ≤2.5 kg
Stronghold Plus 30 mg/5 mg spot-on solution for cats >2.5–5 kg
Stronghold Plus 60 mg/10 mg spot-on solution for cats >5–10 kg

selamectin/sarolaner

3. **STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

Each unit dose (pipette) delivers:

**Active substances:**

<table>
<thead>
<tr>
<th>Stronghold Plus spot-on solution</th>
<th>Total volume of unit dose (ml)</th>
<th>selamectin (mg)</th>
<th>sarolaner (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cats ≤2.5 kg</td>
<td>0.25</td>
<td>15</td>
<td>2.5</td>
</tr>
<tr>
<td>Cats &gt;2.5–5 kg</td>
<td>0.5</td>
<td>30</td>
<td>5</td>
</tr>
<tr>
<td>Cats &gt;5–10 kg</td>
<td>1</td>
<td>60</td>
<td>10</td>
</tr>
</tbody>
</table>

**Excipients:**

0.2 mg/ml butylated hydroxytoluene.

Spot-on solution.
Clear, colourless to yellow solution.

4. **INDICATION(S)**

For cats with, or at risk from, mixed parasitic infestations by ticks and fleas, lice, mites, gastrointestinal nematodes or heartworm. The veterinary medicinal product is exclusively indicated when use against ticks and one or more of the other target parasites is indicated at the same time.

**Ectoparasites:**

- For the treatment and prevention of flea infestations (*Ctenocephalides* spp.). The veterinary medicinal product has immediate and persistent flea killing activity against new infestations for 5 weeks. The product kills adult fleas before they lay eggs for 5 weeks. Through its ovicidal and
larvicidal action, the veterinary medicinal product may aid in the control of existing environmental flea infestations in areas to which the animal has access.

- The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
- Treatment of tick infestations. The veterinary medicinal product has immediate and persistent acaricidal effect for 5 weeks against *Ixodes ricinus* and *Ixodes hexagonus*, and 4 weeks against *Dermacentor reticulatus* and *Rhipicephalus sanguineus*.
- Treatment of ear mites (*Otodectes cynotis*).
- Treatment of biting lice infestations (*Felicola subrostratus*).

Ticks must attach to the host and commence feeding in order to be exposed to sarolaner.

**Nematodes:**

- Treatment of adult roundworms (*Toxocara cati*) and adult intestinal hookworms (*Ancylostoma tubaeforme*).
- Prevention of heartworm disease caused by *Dirofilaria immitis* with monthly administration.

5. **CONTRAINDICATIONS**

Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Do not use in cats that are suffering from concomitant disease, or are debilitated and underweight (for size and age).

6. **ADVERSE REACTIONS**

Use of the veterinary medicinal product may result in mild and transient pruritus at the application site. Mild to moderate alopecia at the application site, erythema and drooling have been uncommonly observed.

The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).

If you notice any serious adverse effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.

7. **TARGET SPECIES**

Cats.

8. **DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

Spot-on use.
Stronghold Plus should be administered as a single spot-on (topical) application in accordance with the following table (corresponding to a minimum of 6 mg/kg selamectin and 1 mg/kg sarolaner).

<table>
<thead>
<tr>
<th>Bodyweight of cat (kg)</th>
<th>Pipette content (ml)</th>
<th>Strength and number of pipettes to be administered</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Stronghold Plus 15 mg/2.5 mg (yellow cap)</td>
</tr>
<tr>
<td>≤2.5</td>
<td>0.25</td>
<td>1</td>
</tr>
<tr>
<td>&gt;2.5–5</td>
<td>0.5</td>
<td>1</td>
</tr>
<tr>
<td>&gt;5–10</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>&gt;10</td>
<td></td>
<td>Appropriate combination of pipettes</td>
</tr>
</tbody>
</table>

**Fleas and ticks**
For optimal control of tick and fleas infestations, the veterinary medicinal product should be administered at monthly intervals and continued throughout the flea and/or tick season based on local epidemiological situations.

Following administration of the product, the adult fleas on the animal are killed within 24 hours, no viable eggs are produced, and larvae (found only in the environment) are also killed. This stops flea reproduction, breaks the flea lifecycle and may aid in the control of existing environmental flea infestations in areas to which the animal has access.

**Prevention of heartworm disease**
The product may be administered year-round or at least within one month of the animal’s first exposure to mosquitoes and monthly thereafter until the end of the mosquito season. The final dose must be given within one month after the last exposure to mosquitoes. If a dose is missed and a monthly interval between dosing is exceeded, then immediate administration of the product and resumption of monthly dosing will minimise the opportunity for the development of adult heartworms. When replacing another heartworm preventive product in a heartworm disease prevention programme, the first dose of the product must be given within a month of the last dose of the former veterinary medicinal product.

**Treatment of roundworm and hookworm infections**
A single dose of the product should be administered. The need for and frequency of re-treatment should be in accordance with the advice of the prescribing veterinarian.

**Treatment of biting lice**
A single dose of the product should be administered.

**Treatment of ear mites**
A single dose of the product should be administered. Seek further veterinary examination 30 days after treatment to determine whether a second administration is necessary.

9. **ADVICE ON CORRECT ADMINISTRATION**
This veterinary medicinal product is to be applied to the skin surface only. Do not administer orally or parenterally.

Do not apply when the animal’s hair coat is wet.

For ear mite treatment, do not apply directly to the ear canal.
It is important to apply the dose as indicated to prevent the animal from licking and ingesting the product. If significant ingestion occurs, transient gastrointestinal effects such as hypersalivation, emesis, soft faeces or reduced food consumption may be observed and should normally resolve without treatment.

Apply topically to the skin at the base of the neck in front of the shoulder blades. The pipette should be removed from the protective package immediately prior to administration.

Holding the pipette upright, firmly depress the cap to puncture the applicator seal, then remove the cap.

Part the hair at the base of the cat’s neck in front of the shoulder blades to expose a small area of skin. Apply the tip of the pipette directly to the skin without massaging.

Squeeze the pipette firmly 3–4 times to empty the contents in one spot. Avoid contact between the product and your fingers.

Transient cosmetic effects may occur at the application site such as temporary clumping or spiking of the hair, greasiness or dry white deposits, which normally resolve within 24 hours after product application. These effects do not affect the safety or efficacy of the veterinary medicinal product.

10. WITHDRAWAL PERIOD

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
Store below 30 °C.
Do not remove the pipette from the blister until ready to use.
Do not use this veterinary medicinal product after the expiry date which is stated on the blister after EXP.

12. SPECIAL WARNING(S)

Special warnings for each target species:
Use of this veterinary medicinal product is indicated in cats aged at least 8 weeks old and weighing at least 1.25 kg bodyweight.

Ticks need to start feeding on the host to become exposed to sarolaner; therefore, the transmission of infectious tick-borne diseases cannot be excluded.
Keep treated animals away from fires and other sources of ignition for at least 30 minutes or until the hair coat is dry.

It is recommended, in accordance with good veterinary practice, that all animals 6 months of age or more, living in countries where a vector exists should be tested for existing adult heartworm infection before beginning preventive use with the veterinary medicinal product.

This veterinary medicinal product is not effective against adult *D. immitis*. The administration to animals with adult heartworm infection did not pose safety concerns.

Whilst not routinely indicated, the potential benefits of performing periodic testing for heartworm infection in individual cases should be considered by the responsible veterinarian.

**Special precautions to be taken by the person administering the veterinary medicinal product to animals**

The product is harmful after ingestion. Keep the product in the original packaging until use, in order to prevent children from getting direct access to the product. Used pipettes should be disposed of immediately. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

The product may cause eye irritation. Avoid eye contact including hand-to-eye-contact. Avoid direct contact with treated animals until the application area is dry. Wash hands after use and wash off any product in contact with the skin immediately with soap and water. If accidental eye exposure occurs, flush the eyes immediately with water and seek medical attention. People with sensitive skin or known allergy to veterinary medicinal products of this type should handle the veterinary medicinal product with caution.

Children are not allowed to play with treated cats for 4 hours after treatment. It is recommended to treat animals in the evening. On the day of treatment, treated animals should not be permitted to sleep in the same bed as their owner, especially children.

The product is highly flammable. Keep away from heat, sparks, open flame or other sources of ignition.

**Pregnancy and lactation:**
The safety of the veterinary medicinal product has not been established during pregnancy and lactation or in animals intended for breeding. However, selamectin is considered safe for use in breeding, pregnant and lactating cats. While the safety of sarolaner has not been evaluated in breeding, pregnant or lactating cats, laboratory studies with sarolaner in rats and rabbits have not produced any evidence of teratogenic effects. Use only according to the benefit-risk assessment by the prescribing veterinarian.

**Interactions with other medicinal products and other forms of interactions:**
During clinical field testing, no interactions between this veterinary medicinal product and routinely used veterinary medicinal products were observed.

**Overdose (symptoms, emergency procedures, antidotes):**
No clinically significant adverse reactions were observed in kittens from 8 weeks of age treated with up to 5 times the maximum recommended dose of the product for up to 8 consecutive treatments at 28 day intervals, apart from a single cat administered 5 times the maximum dose that displayed transient hypersensitivity to touch, piloerection, mydriasis and mild tremor which resolved without treatment.

After accidental ingestion of a full product dose, transient gastrointestinal effects such as salivation, soft faeces, emesis, and reduced food consumption may occur, however these should resolve without treatment.
13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater. Selamectin may adversely affect aquatic organisms. Containers and residual contents should be disposed of along with collected domestic refuse to avoid contamination of any water courses. Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.

15. OTHER INFORMATION

Selamectin is a semi-synthetic compound of the avermectin class. Selamectin has adulticidal, ovicidal and larvicidal activity against fleas. Therefore, it effectively breaks the flea life cycle by killing adults (on the animal), preventing the hatching of eggs (on the animal and in its environment) and by killing larvae (environment only). Debris from selamectin-treated pets kills flea eggs and larvae not previously exposed to selamectin and thus may aid in the control of existing environmental flea infestations in areas to which the animal has access. Selamectin is active against adult fleas (Ctenocephalides spp.) as well as mites (Otodectes cynotis), lice (Felicola subrostratus) and gastrointestinal nematodes (Toxocara cati, Ancylostoma tubaeforme). Activity has also been demonstrated against heartworm (D. immitis) larvae.

For fleas, the onset of efficacy is within 24 hours for 5 weeks after product application.

Sarolaner is an acaricide and insecticide belonging to the isoxazoline family. Sarolaner is active against adult fleas (Ctenocephalides spp.) as well as several tick species such as Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus, and Rhipicephalus sanguineus.

For ticks (I. ricinus), the onset of efficacy is within 24 hours of attachment for one month after product application.

The product is available in packs of three pipettes (all pipette sizes) and six pipettes (all pipette sizes). Not all pack sizes may be marketed.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

België/Belgique/Belgien
Zoetis Belgium SA
Tél/Tel.: +32 (0) 800 99 189

Lietuva
Oriola Vilnius UAB
Tel.: +370 610 05088

Република България
Zoetis Belgium SA
Тел: +359 2 4775791

Luxembourg
Zoetis Belgium SA
Tél/Tel.: +352 8002 4026
Česká republika
Zoetis Česká republika, s.r.o.
Tel: +420 257 101 111

Magyarország
Zoetis Hungary Kft.
Tel: +361 224 5222

Danmark
Orion Pharma Animal Health
Tlf: +45 86 14 00 00

Malta
Agrimed Limited
Tel: +356 21 465 797

Deutschland
Zoetis Deutschland GmbH
Tel: +49 30 330063 0

Nederland
Zoetis B.V.
Tel: +31 (0)10 714 0900

Eesti
Oriola Vilnius UAB
Tel: +370 610 05088

Norge
Orion Pharma Animal Health
Tlf: +47 40 00 41 90

Elλάδα
Zoetis Hellas S.A.
Τηλ.: +30 210 6791900

Österreich
Zoetis Österreich GmbH
Tel: +43 1 2701100 110

España
Zoetis Spain, S.L.
Tel: +34 91 4191900

Polska
Zoetis Polska Sp. z o.o.
Tel: +48 22 2234800

France
Zoetis France
Tél: +33 (0)810 734 937

Portugal
Zoetis Portugal, Lda.
Tel: +351 21 042 3083

Hrvatska
Zoetis Netherlands Holdings BV
Tel: +385 1 644 1460

România
Zoetis România SRL
Tel: +40 21 202 3083

Ireland
Zoetis Belgium SA
Tel: +353 (0) 1 256 9800

Slovenija
Zoetis Netherlands Holdings BV
Tel: +385 1 644 1460

Italy
Zoetis Italia S.r.l.
Tel: +39 06 3366 8133

Slovenská republika
Zoetis Česká republika, s.r.o.
Tel: +420 257 101 111

Kύπρος
Zoetis Hellas S.A.
Τηλ.: +30 210 6791900

Suomi/Finland
Zoetis Finland Oy
Puh/Tel: +358 (0)9 4300 40

Latvija
Oriola Vilnius UAB
Tel: +370 610 05088

Sverige
Orion Pharma Animal Health
Tel: +46 (0)8 623 64 40

United Kingdom
Zoetis UK Limited
Tel: +44 (0) 845 300 8034